Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 0.62 |
| ▸ | MMP2 | P08253 | 11/20 | 0.62 |
| ▸ | MMP3 | P08254 | 9/20 | 0.62 |
| ▸ | MMP8 | P22894 | 6/20 | 0.58 |
| ▸ | MMP9 | P14780 | 5/20 | 0.58 |
| ▸ | MMP7 | P09237 | 4/20 | 0.58 |
| ▸ | FCER2 | P06734 | 3/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19033467 | 0.88 | MEN1 (0.56) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL6469693 | 0.88 | MEN1 (0.56) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL23870352 | 0.88 | FCER2 (0.58) | MMP1MMP2MMP3MMP7FCER2 | |
| SCHEMBL2873585 | 0.87 | MME (0.62) | MMP2MMP9MMP7MMP12MMP13 | |
| SCHEMBL22300787 | 0.86 | MEN1 (0.59) | MMP2MMP9MMP7MMP12MMP13 | |
| SCHEMBL29045685 | 0.84 | MME (0.58) | MMP2MMP9MMP7MMP12MMP13 | |
| SCHEMBL29045684 | 0.84 | MME (0.58) | MMP2MMP9MMP7MMP12MMP13 | |
| SCHEMBL6414154 | 0.84 | MMP1 (0.67) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL23616285 | 0.83 | MME (0.55) | MMP2MMP3MMP9MMP7MMP12 | |
| SCHEMBL7400674 | 0.82 | PSMB5 (0.69) | MMP1MMP2MMP3MMP8MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497365-B2 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. | 2013-07-30 | — | — | US | disclosed |
| WO-2013025490-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | MMP1 1461/4885MMP2 2573/4885MMP3 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.